News

Bridging Study Finds Ripretinib Improves Survival Among Chinese Patients With Advanced Gastrointestinal Stromal Tumors

07/08/2022

Allison Casey

In a phase 2 bridging study of the phase 3 INVICTUS study, ripretinib was found to improve the survival of Chinese patients with advanced gastrointestinal stromal tumors.

In a phase 2 bridging study of...

07/08/2022

Oncology

News

Pimitespib Improves Survival for Patients With Advanced GIST: CHAPTER-GIST-301 Trial

06/15/2022

Allison Casey

Results from a phase 3 CHAPTER-GIST-301 trial show pimitespib significantly improved PFS and crossover-adjusted OS vs placebo for patients with advanced GIST refractory to TKIs.

Results from a phase 3...

06/15/2022

Oncology

News

Long-term Outcomes of Endoscopic Therapy vs Surgical Resection for Gastrointestinal Stromal Tumors

05/04/2022

Janelle Bradley

Study findings reveal no significant difference in long-term survival among patients with gastrointestinal stromal tumors receiving endoscopic therapy vs surgical resection.

Study findings reveal no...

05/04/2022

Oncology

News

Imatinib Plus Binimetinib Found Effective With Manageable Toxicity in Advanced GIST

02/24/2022

The results of a phase 2 trial which evaluated the efficacy and safety of imatinib plus binimetinib in first-line treatment of advanced gastrointestinal stromal tumor (GIST) warranted the comparison of the novel strategy to imatinib alone.

The results of a phase 2 trial...

02/24/2022

Oncology

News

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in GIST

02/24/2022

Study findings reveal avapritinib is not superior to regorafenib for the third-line or later treatment of gastrointestinal stromal tumors (GISTs).

Study findings reveal...

02/24/2022

Oncology

Conference Coverage

Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape

09/14/2021

The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.

The ESMO-MCBS medical device was...

09/14/2021

Oncology

Conference Coverage

Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape

09/14/2021

The ESMO-MCBS medical device was...

09/14/2021

Oncology

Conference Coverage

Driver Mutations Found Targetable for Wild-Type GIST

09/14/2021

Findings from a recent study were shared at the virtual 2021 ESMO Congress to present identifiable, targetable driver mutations for wild-type mutations in GIST and gain insight into developing corresponding targeted therapies.

Findings from a recent study...

09/14/2021

Oncology

Conference Coverage

Driver Mutations Found Targetable for Wild-Type GIST

09/14/2021

Findings from a recent study...

09/14/2021

Oncology

Conference Insider

Phase 3 INVICTUS Trial Demonstrates Ripretinib Benefit in GIST

09/14/2021

Mature data released from the phase 3 INVICTUS trial yields significantly improved PFS, reductions in disease progression, and clinically meaningful OS improvements in advanced gastrointestinal stromal tumors (GIST), presented at the virtual...

Mature data released from the...

09/14/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology